Safety Profile of Statins: An Umbrella Review of Systematic Reviews and Meta-analyses
European Cardiology Review · 22.07.2026
DOI: 10.15420/ecr.2026.03 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Cardiology Review, online erschienen am 22.07.2026. Verfasst von Ana Penedones und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Social Pharmacy and Public Health, Faculty of Pharmacy, University of Coimbra Coimbra, Portugal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Statins are a cornerstone of therapy to reduce LDL cholesterol and cardiovascular diseases. However, their use may cause adverse events. This umbrella review aims to comprehensively review the safety profile of statin therapy.
Methods
PubMed and Embase were searched to identify systematic reviews, scoping reviews, meta-analyses and network meta-analyses on statin safety. Extracted data included study type, data source, number of included studies, search date range, participant numbers, interventions, safety outcomes, results and funding. Risk of bias was assessed using the AMSTAR 2 instrument. Data underwent descriptive statistical analysis.
Results
Seventy-two reviews were included, mostly based on clinical trials (70.8%) and observational studies (59.7%). Only 21 (29.2%) reported results for individual statins, with atorvastatin being the most frequently evaluated individual statin (95.2%). Nearly 86% of the reviews were rated as Critically Low in overall confidence. Statins were associated with an increased risk of new-onset diabetes, particularly rosuvastatin and atorvastatin, whereas pitavastatin may be protective. Liver injury/dysfunction and elevated transaminases were observed, along with a small risk of muscle-related symptoms, specifically at higher statin intensity. Rare serious events, such as necrotising myopathy, were reported. Pregnancy studies indicated an increased risk of spontaneous abortion.
Conclusion
Although overall statin safety is favourable, the risks of diabetes, liver dysfunction, enzyme elevations and muscle symptoms require consideration, especially with high-intensity therapy or specific statins. Pitavastatin may be a safer option for patients at metabolic risk. Therapy should be tailored to individual patient factors. Further research is needed to clarify rare or inconsistent outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Social Pharmacy and Public Health, Faculty of Pharmacy, University of Coimbra Coimbra, Portugal.
- Clevidence Oeiras, Portugal.
- Clinical Pharmacology Unit, Santa Maria Local Health Unit Lisbon, Portugal.
- Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa Lisbon, Portugal.
- Tecnimede SA, Abrunheira Sintra, Portugal.
ORCID-Profile: Ana Penedones, Diogo Mendes, Andreia Rodrigues Lopes, Carlos Alves, Augusto Filipe
Zitieren
APA
Penedones, A., Mendes, D., Rodrigues Lopes, A., Oliveira, T., Alves, C., & Filipe, A. (2026). Safety Profile of Statins: An Umbrella Review of Systematic Reviews and Meta-analyses. European Cardiology Review. https://doi.org/10.15420/ecr.2026.03
Vancouver
Penedones A, Mendes D, Rodrigues Lopes A, Oliveira T, Alves C, Filipe A. Safety Profile of Statins: An Umbrella Review of Systematic Reviews and Meta-analyses. European Cardiology Review. 2026. doi:10.15420/ecr.2026.03
BibTeX
@article{Penedones2026,
author = {Penedones, Ana and Mendes, Diogo and Rodrigues Lopes, Andreia and Oliveira, Tânia and Alves, Carlos and Filipe, Augusto},
title = {Safety Profile of Statins: An Umbrella Review of Systematic Reviews and Meta-analyses},
journal = {European Cardiology Review},
year = {2026},
doi = {10.15420/ecr.2026.03}
}
EUVIMED